Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology

Biosensor Platform Leverages Silicon Semiconductor Manufacturing for Scale Technology Designed to Provide a Better View of Metabolic Health by Combining Glucose Information with Context Around Activities of Daily Living in One Device $58 Million in Funding Led by Alpha Wave Ventures Biolinq Incorporated, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, today announced the completion of $58 million in financing led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital, and Taisho Pharmaceutical. J.P. Morgan served as a placement agent to Biolinq in connection with the financing. The financing will support completion of a U.S. pivotal clinical trial this year, evaluating Biolinq’s proprietary intradermal glucose sensor, and subsequent FDA submission. Designed for simplicity, Biolinq’s wearable patch uses an array of tiny electrochemical sensors to measure glucose levels from the intradermal space just beneath the surface of the skin, combining glucose information with relative levels of activity in one device. “Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said R...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Alpha Wave Ventures Aphelion Capital AXA IM Alts Biolinq Biolinq Incorporated Dan Bradbury Features Capital Global Health Investment Corporation Health IT Funding Health IT Fundings Health IT Investm Source Type: blogs